Back to Search
Start Over
BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study
- Source :
- Louw, A, Panou, V, Szejniuk, W M, Meristoudis, C, Chai, S M, van Vliet, C, Lee, Y C G, Dick, I M, Firth, T, Lynggaard, L A, Asghari, A B, Vyberg, M, Hansen, J, Creaney, J & Røe, O D 2022, ' BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma : A validation study ', Journal of Thoracic Oncology, vol. 17, no. 7, pp. 921-930 . https://doi.org/10.1016/j.jtho.2022.04.008
- Publication Year :
- 2022
- Publisher :
- Elsevier BV, 2022.
-
Abstract
- INTRODUCTION: Pleural mesothelioma (PM) is an aggressive malignancy with no identified predictive biomarkers. We assessed whether tumor BAP1 status is a predictive biomarker for survival in patients receiving first-line combination platinum and pemetrexed therapy.METHODS: PM cases (n = 114) from Aalborg, Denmark, were stained for BAP1 on tissue microarrays. Demographic, clinical, and survival data were extracted from registries and medical records. Surgical cases were excluded. BAP1 status was associated with overall survival (OS) by Cox regression and Kaplan-Meier methods. Results were validated in an independent cohort from Perth, Australia (n = 234).RESULTS: BAP1 loss was found in 62% and 60.3% of all Danish and Australian samples, respectively. BAP1 loss was an independent predictor of OS in multivariate analyses corrected for histological subtype, performance status, age, sex, and treatment (hazard ratio = 2.49, p < 0.001, and 1.48, p = 0.01, respectively). First-line platinum and pemetrexed-treated patients with BAP1 loss had significantly longer median survival than those with retained BAP1 in both the Danish (20.1 versus 7.3 mo, p < 0.001) and Australian cohorts (19.6 versus 11.1 mo, p < 0.01). Survival in patients with BAP1 retained and treated with platinum and pemetrexed was similar as in those with best supportive care. There was a higher OS in patients with best supportive care with BAP1 loss, but it was significant only in the Australian cohort (16.8 versus 8.3 mo, p < 0.01).CONCLUSIONS: BAP1 is a predictive biomarker for survival after first-line combination platinum and pemetrexed chemotherapy and a potential prognostic marker in PM. BAP1 in tumor is a promising clinical tool for treatment stratification.
- Subjects :
- Mesothelioma
Pulmonary and Respiratory Medicine
Lung Neoplasms
Mesothelioma/pathology
Pleural Neoplasms
Tumor Suppressor Proteins
Mesothelioma, Malignant
Australia
Australia/epidemiology
Pleural Neoplasms/pathology
Pemetrexed
Immunohistochemistry
Pemetrexed/therapeutic use
Predictive biomarkers
Oncology
Platinum/therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Chemotherapy
Lung Neoplasms/pathology
Humans
BAP1
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Ubiquitin Thiolesterase
Pleural mesothelioma
Platinum
Subjects
Details
- ISSN :
- 15560864
- Volume :
- 17
- Database :
- OpenAIRE
- Journal :
- Journal of Thoracic Oncology
- Accession number :
- edsair.doi.dedup.....56d4a12d531cfba9a0343a260fa2c6f6